Delaware Court Dismisses AnaptysBio's Claim Against TESARO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GSK?
Source: seekingalpha
- Court Ruling: The Delaware Court of Chancery dismissed AnaptysBio's anticipatory breach of contract claim against TESARO, although the ruling does not address the merits of the main contractual dispute, indicating a cautious judicial stance on the allegations.
- Litigation Background: TESARO initiated this litigation following AnaptysBio's claims of non-fulfillment of the license agreement signed in March 2014, with AnaptysBio intending to revoke TESARO's license for dostarlimab, highlighting significant contractual disagreements between the parties.
- Product Approval Status: Dostarlimab, marketed as Jemperli, is currently approved in over 35 countries for certain endometrial cancers, which is the most common gynecologic cancer in the U.S., showcasing the drug's market potential.
- Company Position: GSK and TESARO firmly believe that these allegations are entirely without merit and remain focused on pursuing a declaratory judgment against AnaptysBio in court, demonstrating the companies' strong commitment to defending their legal rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GSK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GSK
Wall Street analysts forecast GSK stock price to fall
6 Analyst Rating
1 Buy
2 Hold
3 Sell
Moderate Sell
Current: 55.630
Low
20.15
Averages
38.72
High
55.60
Current: 55.630
Low
20.15
Averages
38.72
High
55.60
About GSK
GSK plc is a United Kingdom-based biopharma company. The Company’s segments include Commercial Operations and Research and Development. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The Company also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Delaware Court Dismisses AnaptysBio's Claim Against TESARO
- Court Ruling: The Delaware Court of Chancery dismissed AnaptysBio's anticipatory breach of contract claim against TESARO, although the ruling does not address the merits of the main contractual dispute, indicating a cautious judicial stance on the allegations.
- Litigation Background: TESARO initiated this litigation following AnaptysBio's claims of non-fulfillment of the license agreement signed in March 2014, with AnaptysBio intending to revoke TESARO's license for dostarlimab, highlighting significant contractual disagreements between the parties.
- Product Approval Status: Dostarlimab, marketed as Jemperli, is currently approved in over 35 countries for certain endometrial cancers, which is the most common gynecologic cancer in the U.S., showcasing the drug's market potential.
- Company Position: GSK and TESARO firmly believe that these allegations are entirely without merit and remain focused on pursuing a declaratory judgment against AnaptysBio in court, demonstrating the companies' strong commitment to defending their legal rights.
See More
Regeneron Launches Gene Therapy and Lowers Drug Prices
- Free Gene Therapy: Regeneron announced that its recently FDA-approved gene therapy, Otarmeni, will be provided free of charge in the U.S. to address an ultra-rare form of genetic hearing loss, enhancing the company's image as a socially responsible biopharma leader.
- Drug Price Adjustments: The company will lower Medicaid prices to match those in other developed nations, notably reducing the price of its blockbuster drug Praluent from approximately $537 to $225, which is expected to significantly alleviate patient financial burdens and enhance market competitiveness.
- R&D Investment Commitment: Regeneron has committed over $9 billion to bolster domestic R&D and manufacturing capabilities over the coming years, a strategic investment that will strengthen its innovation and production capacity in the global biopharma market.
- Policy Context and Market Reaction: As the final biopharma firm to sign Trump's drug pricing agreement, Regeneron's actions align with policy expectations and may improve its investor perception, with bullish sentiment reflected on Stocktwits, despite the stock's 0.8% decline year-to-date.
See More
Cerebras Systems Plans Initial Public Offering in AI Chip Market
- IPO Announcement: Cerebras Systems filed a registration statement with the SEC on April 17, 2023, indicating its intent to hold an initial public offering (IPO), although the number of shares and price range remain undetermined, marking a significant step in the rapidly growing AI chip market.
- Competitive Potential: Founded in 2015, Cerebras aims to revolutionize AI computing with wafer-scale technology, positioning itself as a formidable competitor to Nvidia, with its unique CS-2 and CS-3 systems expected to capture substantial market share.
- Expanding Customer Base: Recently, Cerebras secured partnerships with high-profile clients such as OpenAI, Amazon, and Meta, particularly a major multi-year agreement with OpenAI for 750 megawatts of deployment, which is set to become the largest high-speed AI inference deployment globally, further solidifying its market position.
- Strong Financial Performance: According to its SEC filing, Cerebras reported a 76% year-over-year revenue increase to $510 million in 2025, despite an operational loss of $145.9 million, reflecting a significant investment in R&D, which accounted for 48% of annual sales, indicating a strong commitment to technological advancement.
See More
Cerebras Plans IPO on Nasdaq Amid AI Chip Competition
- IPO Announcement: Cerebras filed a registration statement with the SEC on April 17 for its initial public offering (IPO), although the specific date and price range remain undetermined, marking a significant step in its entry into the rapidly growing AI chip market.
- Competitive Potential: Cerebras is viewed as a formidable competitor in the AI chip space, particularly against current market leader Nvidia, as the surging demand in the sector positions Cerebras' innovative technology to attract increased investor interest.
- Expanding Client Base: Recently, Cerebras secured high-profile clients including OpenAI, Amazon, and Meta, with a major 750-megawatt deployment agreement with OpenAI set for 2026, which will establish it as the largest high-speed AI inference deployment globally, further solidifying its market position.
- Strong Financial Performance: According to SEC filings, Cerebras' revenue surged 76% year-over-year to $510 million in 2025, and while it reported an operational loss of $145.9 million, its R&D expenditure accounted for 48% of annual sales, indicating a strong commitment to technological innovation and potential long-term growth prospects.
See More
ANAPTYS FINALIZES DIVESTITURE OF FIRST TRACKS BIOTHERAPEUTICS AND NOW FOCUSES SOLELY ON GSK AND VANDA FINANCIAL PARTNERSHIPS
Separation of First Tracks: ANAPTY has completed the separation of its first tracks in biotherapeutics.
Management of Financial Collaborations: The company now exclusively manages financial collaborations with GSK and Vanda.
See More
Trump Nominates Erica Schwartz as CDC Director
- New CDC Director Nomination: President Trump has nominated Erica Schwartz to lead the Centers for Disease Control and Prevention (CDC), ending a months-long search for a permanent director, with her confirmation pending in the Senate, which could influence the agency's policy direction.
- Health Policy Changes: Schwartz will take over amid controversial health policy changes overseen by Health and Human Services Secretary Robert F. Kennedy Jr., including a comprehensive overhaul of childhood vaccine recommendations, directly impacting public health strategies.
- Extensive Medical Background: Having served as deputy surgeon general during the Trump administration and playing a key role in the U.S. response to the COVID-19 pandemic, Schwartz brings over 20 years of military experience, including as the Coast Guard's chief medical officer, providing strong credentials for her new role.
- Transition from Acting Director: Prior to Schwartz's nomination, Jay Bhattacharya served as acting CDC director, but his term expired last month under federal law, leaving the CDC without a Senate-confirmed leader for months, and Schwartz's appointment is expected to bring new leadership to the agency.
See More
Delaware Court Dismisses AnaptysBio's Claim Against TESARO
- Court Ruling: The Delaware Court of Chancery dismissed AnaptysBio's anticipatory breach of contract claim against TESARO, although the ruling does not address the merits of the main contractual dispute, indicating a cautious judicial stance on the allegations.
- Litigation Background: TESARO initiated this litigation following AnaptysBio's claims of non-fulfillment of the license agreement signed in March 2014, with AnaptysBio intending to revoke TESARO's license for dostarlimab, highlighting significant contractual disagreements between the parties.
- Product Approval Status: Dostarlimab, marketed as Jemperli, is currently approved in over 35 countries for certain endometrial cancers, which is the most common gynecologic cancer in the U.S., showcasing the drug's market potential.
- Company Position: GSK and TESARO firmly believe that these allegations are entirely without merit and remain focused on pursuing a declaratory judgment against AnaptysBio in court, demonstrating the companies' strong commitment to defending their legal rights.
See More
Regeneron Launches Gene Therapy and Lowers Drug Prices
- Free Gene Therapy: Regeneron announced that its recently FDA-approved gene therapy, Otarmeni, will be provided free of charge in the U.S. to address an ultra-rare form of genetic hearing loss, enhancing the company's image as a socially responsible biopharma leader.
- Drug Price Adjustments: The company will lower Medicaid prices to match those in other developed nations, notably reducing the price of its blockbuster drug Praluent from approximately $537 to $225, which is expected to significantly alleviate patient financial burdens and enhance market competitiveness.
- R&D Investment Commitment: Regeneron has committed over $9 billion to bolster domestic R&D and manufacturing capabilities over the coming years, a strategic investment that will strengthen its innovation and production capacity in the global biopharma market.
- Policy Context and Market Reaction: As the final biopharma firm to sign Trump's drug pricing agreement, Regeneron's actions align with policy expectations and may improve its investor perception, with bullish sentiment reflected on Stocktwits, despite the stock's 0.8% decline year-to-date.
See More
Cerebras Systems Plans Initial Public Offering in AI Chip Market
- IPO Announcement: Cerebras Systems filed a registration statement with the SEC on April 17, 2023, indicating its intent to hold an initial public offering (IPO), although the number of shares and price range remain undetermined, marking a significant step in the rapidly growing AI chip market.
- Competitive Potential: Founded in 2015, Cerebras aims to revolutionize AI computing with wafer-scale technology, positioning itself as a formidable competitor to Nvidia, with its unique CS-2 and CS-3 systems expected to capture substantial market share.
- Expanding Customer Base: Recently, Cerebras secured partnerships with high-profile clients such as OpenAI, Amazon, and Meta, particularly a major multi-year agreement with OpenAI for 750 megawatts of deployment, which is set to become the largest high-speed AI inference deployment globally, further solidifying its market position.
- Strong Financial Performance: According to its SEC filing, Cerebras reported a 76% year-over-year revenue increase to $510 million in 2025, despite an operational loss of $145.9 million, reflecting a significant investment in R&D, which accounted for 48% of annual sales, indicating a strong commitment to technological advancement.
See More
Cerebras Plans IPO on Nasdaq Amid AI Chip Competition
- IPO Announcement: Cerebras filed a registration statement with the SEC on April 17 for its initial public offering (IPO), although the specific date and price range remain undetermined, marking a significant step in its entry into the rapidly growing AI chip market.
- Competitive Potential: Cerebras is viewed as a formidable competitor in the AI chip space, particularly against current market leader Nvidia, as the surging demand in the sector positions Cerebras' innovative technology to attract increased investor interest.
- Expanding Client Base: Recently, Cerebras secured high-profile clients including OpenAI, Amazon, and Meta, with a major 750-megawatt deployment agreement with OpenAI set for 2026, which will establish it as the largest high-speed AI inference deployment globally, further solidifying its market position.
- Strong Financial Performance: According to SEC filings, Cerebras' revenue surged 76% year-over-year to $510 million in 2025, and while it reported an operational loss of $145.9 million, its R&D expenditure accounted for 48% of annual sales, indicating a strong commitment to technological innovation and potential long-term growth prospects.
See More
ANAPTYS FINALIZES DIVESTITURE OF FIRST TRACKS BIOTHERAPEUTICS AND NOW FOCUSES SOLELY ON GSK AND VANDA FINANCIAL PARTNERSHIPS
Separation of First Tracks: ANAPTY has completed the separation of its first tracks in biotherapeutics.
Management of Financial Collaborations: The company now exclusively manages financial collaborations with GSK and Vanda.
See More
Trump Nominates Erica Schwartz as CDC Director
- New CDC Director Nomination: President Trump has nominated Erica Schwartz to lead the Centers for Disease Control and Prevention (CDC), ending a months-long search for a permanent director, with her confirmation pending in the Senate, which could influence the agency's policy direction.
- Health Policy Changes: Schwartz will take over amid controversial health policy changes overseen by Health and Human Services Secretary Robert F. Kennedy Jr., including a comprehensive overhaul of childhood vaccine recommendations, directly impacting public health strategies.
- Extensive Medical Background: Having served as deputy surgeon general during the Trump administration and playing a key role in the U.S. response to the COVID-19 pandemic, Schwartz brings over 20 years of military experience, including as the Coast Guard's chief medical officer, providing strong credentials for her new role.
- Transition from Acting Director: Prior to Schwartz's nomination, Jay Bhattacharya served as acting CDC director, but his term expired last month under federal law, leaving the CDC without a Senate-confirmed leader for months, and Schwartz's appointment is expected to bring new leadership to the agency.
See More
